Literature DB >> 16566721

Positron emission tomography imaging of tumor response after photodynamic therapy.

Veronique Berard1, Roger Lecomte, Johan E van Lier.   

Abstract

Positron emission tomography (PET) imaging is a powerful noninvasive tool allowing physiological and biochemical processes to be investigated in vivo at the molecular level. In the clinics, it is currently being used to detect and stage cancer and to assess tumor response following therapy. In cancer research, at the preclinical level, PET in conjunction with a dedicated high-resolution small animal scanner can play an important role in drug development as well as in the evaluation of novel treatment protocols. In this paper, we review the use of PET in assessing tumor response to photodynamic therapy (PDT) and discuss its potential role in the development of novel photosensitizers. This molecular imaging modality is particularly promising for the real-time evaluation of tumor response to therapy both in terms of treatment efficacy and action mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16566721     DOI: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.150

Source DB:  PubMed          Journal:  J Environ Pathol Toxicol Oncol        ISSN: 0731-8898            Impact factor:   3.567


  4 in total

1.  Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland.

Authors:  Zheng Huang; Masoom A Haider; Susan Kraft; Qun Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Lasers Surg Med       Date:  2006-08       Impact factor: 4.025

Review 2.  Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges.

Authors:  Alyssa Master; Megan Livingston; Anirban Sen Gupta
Journal:  J Control Release       Date:  2013-03-06       Impact factor: 9.776

Review 3.  Photodynamic therapy for treatment of solid tumors--potential and technical challenges.

Authors:  Zheng Huang; Heping Xu; Arlen D Meyers; Ali I Musani; Luowei Wang; Randall Tagg; Al B Barqawi; Yang K Chen
Journal:  Technol Cancer Res Treat       Date:  2008-08

4.  Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Authors:  A T Byrne; A E O'Connor; M Hall; J Murtagh; K O'Neill; K M Curran; K Mongrain; J A Rousseau; R Lecomte; S McGee; J J Callanan; D F O'Shea; W M Gallagher
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.